Insulet (NASDAQ:PODD) Given New $370.00 Price Target at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn has raised Insulet's price target from $350.00 to $370.00, indicating a potential upside of 19.70% from the company's previous close, while maintaining a "buy" rating.
• Insulet reported strong earnings, with $1.17 earnings per share for the last quarter, exceeding estimates and showing a 32.9% year-over-year revenue growth.
• A majority of analysts have rated Insulet stock as a "buy," contributing to a consensus rating of "Moderate Buy" and an average target price of $346.83.

Insulet (NASDAQ:PODD - Get Free Report) had its price objective raised by Rothschild & Co Redburn from $350.00 to $370.00 in a note issued to investors on Friday,MarketScreener reports. The firm presently has a "buy" rating on the medical instruments supplier's stock. Rothschild & Co Redburn's price target points to a potential upside of 19.70% from the company's previous close.

Several other brokerages have also issued reports on PODD. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Oppenheimer raised their target price on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a report on Monday, September 8th. Citigroup reaffirmed a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. JPMorgan Chase & Co. boosted their target price on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a report on Friday, September 12th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $346.83.

Insulet Stock Performance

Shares of PODD opened at $309.11 on Friday. The business's 50 day moving average price is $321.34 and its 200-day moving average price is $298.54. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $21.76 billion, a P/E ratio of 93.95, a P/E/G ratio of 2.59 and a beta of 1.40. Insulet has a 52 week low of $225.37 and a 52 week high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business's revenue was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts anticipate that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Activity at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Prem Singh sold 687 shares of the business's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Institutional Investors Weigh In On Insulet

A number of large investors have recently bought and sold shares of PODD. Larson Financial Group LLC boosted its holdings in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 81 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in Insulet during the first quarter valued at $26,000. SouthState Corp boosted its holdings in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new stake in Insulet during the 2nd quarter worth about $32,000. Finally, Golden State Wealth Management LLC raised its stake in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock valued at $32,000 after buying an additional 69 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.